يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"А. Иванова К."', وقت الاستعلام: 0.29s تنقيح النتائج
  1. 1
    Academic Journal

    المصدر: Malignant tumours; Том 9, № 1 (2019); 16-21 ; Злокачественные опухоли; Том 9, № 1 (2019); 16-21 ; 2587-6813 ; 2224-5057

    وصف الملف: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/611/419; Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2016 году, Москва 2017 (стр.157).; Мерабишвили В. М. Злокачественные новообразования в северо западном федеральном округе России (заболеваемость, смертность, контингенты, выживаемость больных), выпуск третий под ред. Беляева А. М, СПб,2017, стр.22 32.; Journal of Clinical Oncology,27,19, 01.07.2009.; D. Sargent ASCO 2014,#3507; Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии, версия 2017 (стр.261 264).; Expression pattern of CXC chemokine receptor 4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Masahiro Kato, Joji Kitayama, Shinsuke Kazama, Hirokazu Nagawa; Breast Cancer Research, October,2003.; Чердынцева Н. В., Гервас П. А., Литвяков Н. В. с соавт. Хемокины и прогрессия злокачественных новообразований. Медицинская Иммунология.–2006. – Т. 8, – № 2 3. – С.355 356.; А. С. Симбирцев Цитокины: классификация и биологические функции // Цитокины и воспаление. 2004. Том 3 № 2. – С.16 22.; Strieter R. M., Polverini P. J., Kunkel S. L. et al. The functional role of the ELR motif in CXC chemokine mediated angiogenesis. J Biol Chem. 1995. 270 (45): 27348 57.; Rivera CG, Bader JS, Popel AS. Angiogenesis associated crosstalk between collagens, CXC chemokines, and thrombospondin domain containing proteins. Ann Biomed Eng. 2011; 39 (8):2213 22.; Бережная Н. М., Чехун В. Ф. Иммунология злокачественного роста – 2005; Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50 56.; Zeelenberg IS, Ruuls Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003 Jul 1; 63 (13):3833 9.; Sehgal, A., Keener, C., Boynton, AL., Warrick, J., and Murphy, GP. CXCR 4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells.1998. J. Surg. Oncol. 69, 99 104; Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H, Sato M. Possible role of stromal cellderived factor 1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003. 290: 289 302.; Yu X et all J Exp Clin Cancer Res. 2019 Jan 24;38 (1):32. doi:10.1186/s13046-018-1014-x. CXCL12/CXCR4 promotes inflammation driven colorectal cancer -progression through activation of RhoA signaling by sponging miR 133a 3p.; Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DS. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the associa tion with disease outcome. Ann Surg. 2006 Jul; 244 (1):113 20.; https://www.malignanttumors.org/jour/article/view/611

  2. 2
    Academic Journal

    المصدر: Advances in Molecular Oncology; Том 4, № 1 (2017); 35-39 ; Успехи молекулярной онкологии; Том 4, № 1 (2017); 35-39 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2017-4-1

    وصف الملف: application/pdf

    Relation: https://umo.abvpress.ru/jour/article/view/86/100; Горбунова В.А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М.: Кодекс, 2015. 456 с. [Gorbunova V.A. Neuroendocrine tumors. General principles of diagnostics and treatment. Moscow: Kodeks, 2015. 456 p. (In Russ.)].; Симоненко В.Б., Дудин П.А., Маканин М.А. Нейроэндокринные опухоли. М.: ГЭОТАР- Медиа, 2010. 237 с. [Simonenko V.B., Dudin P.A., Makanin M.A. Neuroendocrine tumors. Moscow: GEOTAR-Media, 2010. 237 p. (In Russ.)].; WHO classification of tumors the digestive system. Ed. by F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise. Lyon: IARC Press, 2010.; WHO classification of tumours of the lung, pleura, thymus and heart. Ed. by W.D. Travis, E. Brambilla, A.P. Burke et al. Lyon: IARC Press, 2015.; Sorbye H., Welin S., Langer S.W. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24(1): 152–60.; Khan S., Luong T.V., Watkins J. et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 2013;108(9):1838–45.; Scarpa A., Mantovani W., Capelli P. et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23(6):824–33.; Arco D.D., Pérez D., Medina O. et al. Reliability of Ki-67 determination in FNA samples for grading pancreatic neuroendocrine tumors. Endocr Pathol 2016;27(4):276–83.; Farrell J.M., Pang J.C., Kim G.E., Tabatabai Z.L. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol 2014;122(10): 770–8.; Kleist B., Poetsch M. Neuroendocrine differentiation: The mysterious fellow of colorectal cancer. World J Gastroenterol 2015;21(41):11740–7.; Sentani K., Oue N., Noguchi T. et al. Immunostaining of gastric cancer with neuroendocrine differentiation: Reg IV-positive neuroendocrine cells are associated with gastrin, serotonin, pancreatic polypeptide and somatostatin. Pathol Int 2010;60(4):291–7.; Swarts D.R., van Suylen R.J., den Bakker M.A. et al. Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 2014;38(10):1429–36.; Takeuchi K., Togashi Y., Kamihara Y. et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALKpositive lung cancer (AF-001JP study). Ann Oncol 2016;27(1):185–92.; WHO classification of tumours of the breast. Ed. by S.R. Lakhani, I.O. Ellis, S.J. Schnitt et al. Lyon: IARC Press, 2012.; Gao L.X., Liu G., Li L. et al. Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping. Zhonghua Bing Li Xue Za Zhi 2011;40(9):604–9.; WHO classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Ed. by F.A. Tavassoli, P. Devilee. Lyon: IARC Press, 2003.; Miremadi A., Pinder S.E., Lee A.H. et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002;40(3):215–22.; Inno A., Bogina G., Turazza M. et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist 2016;21(1):28–32.; Wei B., Ding T., Xing Y. et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 2010;116(19):4463–73.; Tian Z., Wei B., Tang F. et al. Prognosticsignificance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 2011;42(8):1169–77.; Kwon S.Y., Bae Y.K., Gu M.J. et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 2014;64(5):647–59.; https://umo.abvpress.ru/jour/article/view/86